Ruxolitinib cream + Vehicle
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-segmental Vitiligo
Conditions
Non-segmental Vitiligo
Trial Timeline
Oct 3, 2019 → Oct 1, 2021
NCT ID
NCT04057573About Ruxolitinib cream + Vehicle
Ruxolitinib cream + Vehicle is a phase 3 stage product being developed by Incyte for Non-segmental Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT04057573. Target conditions include Non-segmental Vitiligo.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906628 | Phase 2 | Completed |
| NCT05219864 | Phase 3 | Withdrawn |
| NCT05233410 | Phase 3 | Withdrawn |
| NCT05127421 | Phase 2 | Completed |
| NCT04057573 | Phase 3 | Completed |
| NCT04052425 | Phase 3 | Completed |
Competing Products
8 competing products in Non-segmental Vitiligo
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR0302 Tablets + SHR0302 Base Gel + SHR0302 Placebo Tablets + SHR0302 Base Placebo Gel | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| MK-6194 + Placebo | Merck | Phase 2 | 52 |
| GIA632 + Placebo | Novartis | Phase 2 | 52 |
| PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841 | Pfizer | Phase 2 | 51 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Roflumilast topical 0.3% foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| VYN201 Gel + Vehicle Gel | Vyne Therapeutics | Phase 2 | 44 |